NRx Submits Emergency Use Authorization Application for ZYESAMI in Patients at RIsk of Death from COVID

 Requested indication focuses on patients whose respiratory failure has progressed despite treatment with Remdesivir or other approved therapies

- Patients treated with ZYESAMI vs. placebo demonstrated statistically significant (P=.03), 2.8-fold increased odds of being alive and free of respiratory failure at day 28 and day 60 and a 4-fold increased odds of surviving to 60 days (P=.006)

- Patients at highest risk - those on ventilators at time of randomization - demonstrated a 10-fold increased odds of survival (P=.03)

- US National Institutes of Health-sponsored trial comparing ZYESAMI and Remdesivir individually and in combination continues to demonstrate safety and has enrolled more than 350 patients

https://finance.yahoo.com/news/nrx-pharmaceuticals-submits-emergency-authorization-114800038.html